Patent Cliff: Key Indicators Investors Should Track Before Loss of Exclusivity

An overview of the pharmaceutical patent cliff and the key indicators to monitor as loss of exclusivity drives generic and biosimilar competition and accelerates revenue erosion.

Introduction

Patent protection is the foundation of the modern pharmaceutical business model. By granting exclusivity for commercializing a drug, patents allow developers to recover years of R&D investment and generate extremely high-margin revenue needed to sustain future innovation. However, this scale of profitability immediately stops when the patent expires. The reason for that is generic or biosimilar competitors quickly enter the market, which causes severe revenue erosion. This transition from peak earnings during exclusivity to a sharp decline after patent expiration is known as the patent cliff. Particularly for companies that depend heavily on a small number of top-selling therapies or are over-concentrated in their pipeline developments, the patent cliff can cause significant problems in long-term valuation.

1. How Patents and Exclusivity Drive Drug Profitability

Patents, in practice, allow pharmaceutical companies to exclusively commercialize a drug with much higher-margin revenue. For a novel therapy targeting a disease with no effective existing treatment, this often results in high market penetration, meaning most of the potential patient population will adopt the new treatment. Such a scale of profitability not only pays back the development costs for the successful product but also helps finance ongoing research and development for future pipelines. Exclusivity is especially critical because pharmaceutical innovation is a high-cost, high-risk process in which most drug candidates fail before reaching the market. The small fraction that becomes meaningful revenue contributors must generate enough profit to cover the losses from failed cases. The patent and exclusivity system are a carefully designed mechanism to maximize innovation and development in the pharmaceutical and biotech industries, and the high margins during exclusivity are therefore justifiable.

In the United States, patents typically last 20 years from the date of filing according to Patent and Trademark Office. However, a large portion of that term is consumed by preclinical research, Phase 1–3 clinical trials, and FDA review. As a result, most therapies experience a real commercial exclusivity period of roughly 8–12 years after approval. Companies may receive patent-term extensions in some cases, which can serve as an important factor in evaluating the commercial lifespan of a drug.

2. Why Profit Falls After Patent Expiry: Generic and Biosimilar Competition

The speed and scale of the post-patent profit declining depends on several factors, primarily depends on therapeutic category and number of competitors entering the market. In cases where a drug does not have significant advantages over alternatives, revenue erosion can easily exceed 80% within the first two years of loss of exclusivity.

For small-molecule drugs, generic versions are chemically identical and inexpensive to produce, enabling manufacturers to offer them at discounts of 70–90% compared to the branded product according to FDA. Take a classic patent cliff case Lipitor, which commercialized by Pfizer, as an example. Lipitor is a small‒molecule statin widely used to lower LDL cholesterol and reduce cardiovascular risk in patients with hyperlipidaemia and coronary artery disease. Lipitor was first approved in 1996 and reached its peak in 2006 after expanded globally with annual sales of $13B. According to SEC, its main US patent expired at the end of November 2011 and within a year its sales reportedly fell to $3.9B and then to just $357M in 2014. This case shows that how dramatic plunge the generics alternatives can cause once exclusivity ended based on data from SEC.

For biologics, the dynamic is similar but somewhat slower. Biosimilars are not exact chemical copies, and their development requires more complex manufacturing, validation, and regulatory processes. These factors typically lead to a more gradual decline in sales rather than the collapse seen with generics. For instance, Humira (adalimumab) commercialized by AbbVie. Humira is a biologic monoclonal antibody used to treat autoimmune conditions which got approved from FDA back in 2002. By 2015, adalimumab was able to generate global sales of $13B annually. Although the original composition-of-matter patent expired in December 2016 in US, other patents delayed biosimilar launch until early 2023, due to the settlements and patent-thicket mechanisms. After biosimilars entered the US market, adalimumab sales dropped 32% compares to prior periods. With nine additional biosimilar competitors start to compete directly with adalimumab, it significantly increases price pressure and reducing branded share.

3. Patent Cliff Risk: Revenue Concentration and Pipeline Strategy

It is common for pharmaceutical companies to exhibit a high degree of revenue concentration around a very limited number of products due to the fact that identifying a truly effective biological target remains extremely challenging. In addition, translating that target into an approved therapy requires years of clinical trials and substantial investment, with highly uncertain regulatory results. Based on statistical data in the biotech industry, only a very small fraction of drug candidates can enter clinical trials and achieve regulatory approval, which makes the emergence of a commercially successful drug a highly exceptional outcome.

Therefore, once a target has proven to be clinically valid or a drug has received regulatory approval, it is reasonable for pharmaceutical companies to invest heavily in promising targets and run clinical trials across all potentially effective diseases in order to expand the drug’s indications. Eli Lilly’s development of tirzepatide is a great example. The molecule was initially developed and approved for type 2 diabetes as Mounjaro, and later was successfully developed and approved for obesity as Zepbound, substantially broadening its commercial reach and making it a blockbuster across multiple indications. This expansion into weight-loss therapy has driven explosive growth in sales of its diabetes and obesity drugs, helping Lilly’s stock rise more than 35% in 2025 and pushing the company to a market valuation above $1 trillion, a rare milestone for a drugmaker, as investors rewarded the revenue and profit growth stemming from the expanded indications of tirzepatide.

This dynamic explains why revenue concentration is inevitable in the pharmaceutical industry rather than merely a strategic error or mismanagement. On the one hand, the probability-adjusted cost of developing a new drug is expected to be extremely high. On the other hand, an approved drug with proven safety and efficacy provides a platform that can be leveraged to access multiple markets, which maximizes return on invested capital within the limited period of patent protection. Consequently, firms naturally become heavily dependent on one or two flagship products for the majority of their revenue base.

However, this concentration creates significant exposure to patent expiration risk, commonly referred to as the “patent cliff.” Once the patents for key method of use or formulation expire, all commercial sales channels related to the drug can be significantly impacted. Although generics may not be able to replace every indication immediately, pricing will still face substantial pressure. Even major pharmaceutical companies such as Pfizer and Merck can face serious valuation challenges due to upcoming patent expirations of their main products, which makes the patent cliff one of the most important considerations in biotech valuation and investment.

Key takeaway

Q1: Why is the patent cliff a major valuation risk for pharmaceutical investors?

Patent expiry removes market exclusivity, enabling rapid generic or biosimilar entry, which drives steep revenue erosion and compresses margins.

Q2: What patent types most affect post-exclusivity drug pricing pressure?

Composition-of-matter, formulation, manufacturing process, dosage regimen, and method-of-use patents determine pricing and competitor timing.

Q3: How long is real commercial exclusivity after FDA drug approval?

Most drugs see about 8–12 years of effective post-approval exclusivity due to time consumed by trials and regulatory review.

Q4: Why do pharma companies expand indications on already approved targets?

Proven targets lower incremental clinical risk and increase total addressable market, maximizing return before patent protection ends.

Q5: How do generics vs biosimilars differ in patent-cliff revenue impact speed?

Generics cause faster share loss due to identical chemistry and deep discounts, while biosimilar competition is strong but slightly slower due to complex manufacturing.
References

← Back to All Insights

24